Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)

Trial Profile

Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 03 May 2017

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Expanded access; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 03 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top